Aurinia Pharmaceuticals Inc AUPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AUPH is a good fit for your portfolio.
News
-
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
-
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
-
Aurinia to Participate in Upcoming Investor Healthcare Conferences
-
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
-
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
Trading Information
- Previous Close Price
- $4.99
- Day Range
- $4.92–5.06
- 52-Week Range
- $4.71–12.43
- Bid/Ask
- $4.86 / $5.65
- Market Cap
- $730.32 Mil
- Volume/Avg
- 1.2 Mil / 2.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.07
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 300
- Website
- https://www.auriniapharma.com
Comparables
Valuation
|
Metric
|
AUPH
|
BLU
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.90 | 5.83 | 12.65 |
Price/Sales | 4.07 | — | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
AUPH
BLU
CBAY
Financial Strength
|
Metric
|
AUPH
|
BLU
|
CBAY
|
|---|---|---|---|
Quick Ratio | 4.85 | 32.13 | 10.70 |
Current Ratio | 5.50 | 33.42 | 10.96 |
Interest Coverage | −33.04 | −1,125.80 | −5.27 |
Quick Ratio
AUPH
BLU
CBAY
Profitability
|
Metric
|
AUPH
|
BLU
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −7.67% | −21.75% | −30.06% |
Return on Equity (Normalized) | −10.09% | −26.24% | −51.97% |
Return on Invested Capital (Normalized) | −11.04% | −24.47% | −30.87% |
Return on Assets
AUPH
BLU
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tczgdqdtqf | Tyxk | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dpmvvnwr | Nfhcmyd | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lgxzbcny | Mvbrjvn | $98.8 Bil | |
MRNA
| Moderna Inc | Blxldgqm | Ngh | $38.8 Bil | |
ARGX
| argenx SE ADR | Kdtbrvfn | Bkld | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Hmkmgmprj | Bplxr | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mxfxmjvjc | Ynvfwh | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ydgqjzzg | Zzbtpbm | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lfvynplqqh | Sqkbsp | $12.4 Bil | |
INCY
| Incyte Corp | Ghgnfjgp | Pzbdyzw | $11.9 Bil |